Señales en vivo de BIXT | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 abr 2024 @ 15:35):

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans...

Stats
Volumen de hoy	91 490.00
Volumen promedio	106 849
Capitalización de mercado	15.85M
EPS	$-0.00734 ( 2023-11-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.65
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Milanova Radka	Buy	70 423	common
2024-04-19	Conaway Dale H	Buy	70 423	common
2024-04-19	Hoberman Alan M	Buy	70 423	common
2024-04-19	Milanova Radka	Sell	0	common
2024-03-27	Utter Anders	Buy	266 955	common

INSIDER POWER
89.94
Last 84 transactions
Buy: 33 376 843 \| Sell: 11 429 961

Bioxytran, Inc. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Bioxytran, Inc. Finanzas

Annual	2022
Ingresos:	$0
Beneficio Bruto:	$-3 644.00 (0.00 %)
EPS:	$-0.0214

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-3 644.00 (0.00 %)
EPS:	$-0.0214

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.0420

FY	2020
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.0271

Financial Reports:

No articles found.

Bioxytran, Inc.

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.